biote Corp.

Equities

BTMD

US0906831039

Professional Information Services

Market Closed - Nasdaq Other stock markets 21:00:00 24/05/2024 BST			5-day change	1st Jan Change
6.35 ^USD	+7.63%		+12.59%	+28.54%

05-20	Biote Shares Fall After Report by Short-Seller J Capital	MT
05-10	Biote Corp. acquired Certain assets of BioSana ID LLC for $0.8 million.	CI

Biote Corp. acquired Certain assets of BioSana ID LLC for $0.8 million.

May 09, 2024

biote Corp. (NasdaqGM:BTMD) executed an asset purchase agreement to acquire Certain assets of BioSana ID LLC for $0.8 million on January 29, 2024. The consideration includes $0.7 million in cash and $0.1 million future earnout payment upon the achievement of certain operating metrics.

biote Corp. (NasdaqGM:BTMD) completed the acquisition of Certain assets of BioSana ID LLC on January 29, 2024.

Latest news about biote Corp.

Biote Shares Fall After Report by Short-Seller J Capital	05-20	MT
Biote Corp. acquired Certain assets of BioSana ID LLC for $0.8 million.	05-09	CI
Earnings Flash (BTMD) BIOTE Reports Q1 Revenue $46.8M, vs. Street Est of $45.7M	05-07	MT
Transcript : Biote Corp., Q1 2024 Earnings Call, May 07, 2024	05-07
Biote Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Biote Corp. Reaffirms Earnings Guidance for the Year 2024	05-07	CI
B. Riley Ups Price Target on Biote to $10 From $9, Maintains Buy Rating	04-05	MT
CORRECTION : --B. Riley Lowers Bitcoin Depot's Price Target to $4 From $6, Maintains Buy Rating	04-03	MT
B. Riley Lowers biote's PT to $4 From $6 After Lower-Than-Expected Q4 2023 Results, Says California Regulations Hit Sales Outlook; Maintains Buy Rating	03-26	MT
Biote Corp. completed the acquisition of Asteria Health.	03-13	CI
Roth MKM Adjusts Price Target on Biote to $9 From $8, Maintains Buy Rating	03-13	MT
Transcript : Biote Corp., Q4 2023 Earnings Call, Mar 12, 2024	03-12
Biote Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-12	CI
Biote Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	03-12	CI
Earnings Flash (BTMD) BIOTE Reports Q4 Revenue $45.7M, vs. Street Est of $45.7M	03-12	MT
Biote Corp. Provides Revenue Guidance for 2024	03-12	CI
B. Riley Securities Starts biote With Buy Rating, $9 Price Target	02-20	MT
Jefferies Starts Biote With Buy Rating, $6.55 Price Target	02-01	MT
Tech Stocks Drag Down Exchange-Traded Funds, Equity Futures Pre-Bell Friday	01-26	MT
Biote Board Approves $20 Million Share Repurchase Program	01-26	MT
Biote Corp. announces an Equity Buyback for $20 million worth of its shares.	01-25	CI
Biote Corp. authorizes a Buyback Plan.	01-24	CI
Sector Update: Health Care Stocks Mixed Premarket Thursday	01-18	MT
Roth MKM Trims Price Target on Biote to $7 From $8, Maintains Buy Rating	01-18	MT
Sector Update: Health Care	01-18	MT

Chart biote Corp.

Duration

Period

More charts

Company Profile

biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Methodâs proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.

Sector

Professional Information Services

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company